Publications by authors named "Ryan E Bash"

Claim this Profile
I
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastoma.
Benjamin Lin, Abigail K Shelton, Erin Smithberger, Julia Ziebro, Kasey R Skinner, Ryan E Bash

Acta Neuropathol Commun· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An in vivo model of glioblastoma radiation resistance identifies long noncoding RNAs and targetable kinases.
Christian T Stackhouse, Joshua C Anderson, Zongliang Yue, Thanh Nguyen, Nicholas J Eustace, Ryan E Bash

JCI Insight· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.
Yu-Ting Su, Madison Butler, Meili Zhang, Wei Zhang, Hua Song, Ryan E Bash

Neurooncol Adv· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition.
Robert S McNeill, Emily E Stroobant, Erin Smithberger, Demitra A Canoutas, Madison K Butler, Ryan E Bash

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MerTK as a therapeutic target in glioblastoma.
Jing Wu, Lauren N Frady, Ryan E Bash, Stephanie M Cohen, Allison N Schorzman

Neuro Oncol· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
Robert S McNeill, Demitra A Canoutas, Timothy J Stuhlmiller, Harshil D Dhruv, David M Irvin, Ryan E Bash

Neuro Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Amanda E D Van Swearingen, Maria J Sambade, Marni B Siegel, Shivani Sud, Robert S McNeill, Ryan E Bash

Neuro Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.
Mark Vitucci, David M Irvin, Robert S McNeill, Ralf S Schmid, Jeremy M Simon, Ryan E Bash

Neuro Oncol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models.
David M Irvin, Robert S McNeill, Ryan E Bash, C Ryan Miller

Brain Pathol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.
Onyinyechukwu Okolie, Juli R Bago, Ralf S Schmid, David M Irvin, Ryan E Bash

Neuro Oncol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
Ralf S Schmid, Jeremy M Simon, Mark Vitucci, Robert S McNeill, Ryan E Bash

Neuro Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling astrocytoma pathogenesis in vitro and in vivo using cortical astrocytes or neural stem cells from conditional, genetically engineered mice.
Robert S McNeill, Ralf S Schmid, Ryan E Bash, Mark Vitucci, Kristen K White

J Vis Exp· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.
Mark Vitucci, Natalie O Karpinich, Ryan E Bash, Andrea M Werneke, Ralf S Schmid

Neuro Oncol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis